For 80% of colorectal cancers, Janus kinase (JAK) inhibitors may be effective
the ONA take:
According to a new study published in the journal Science Signaling, a team of researchers from around the world has demonstrated that more than 80% of colorectal cancers could be treated with Janus kinase (JAK) inhibitors. For the study, researchers tested JAK inhibitors in preclinical models of colorectal cancer and human colorectal cancer cells that have elevated levels of Wnt signaling.
A genetic mutation triggers increases levels Wnt pathway signaling, which in turn triggers more than 80% of colorectal cancers. According to the researchers, targeting the Wnt signaling pathway is difficult because normal cells in the intestine require low levels of Wnt signaling to maintain the healthiness of the gut.
The researchers sought to determine whether another signaling pathway, which involves JAK proteins, could be targeted to decrease tumor growth without harming the normal cells of the intestine. They found that inhibiting JAKs could halt cancer growth and no adverse effects were observed in the preclinical models; however, JAK inhibitors were only effective when the colorectal tumors were triggered by defective Wnt signaling, which is about 80-90% of colorectal cancers.
There are currently no JAK inhibitors approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer.
More than 80% of colorectal cancers could be treated with Janus kinase inhibitors
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|